Document Detail


Chemoprevention of colorectal cancer - a new target needed?
MedLine Citation:
PMID:  17504335     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Novel treatments for colorectal cancer (CRC) include chemoprevention. Nonsteroidal anti-inflammatory drugs (NSAIDs) were the first to be studied and an inverse association was proven between their use and the development of invasive CRC. The numerous side effects of NSAIDs led, however, to the search for safer drugs. These have included Coxibs (selective COX-2 inhibitors). In this study, the role of coxibs in the chemoprevention of CRC is reviewed. RESULTS: Numerous in-vitro and in-vivo experiments have shown the effectiveness of coxibs in the chemoprevention of CRC. These have led to the registration of celecoxib by the USA Food and Drug Administration for the treatment of familial adenomatous polyposis. Further studies of coxibs have revealed an increased risk of serious cardiovascular events when compared with placebo. This finding has considerably decreased the opportunities for chemoprevention of CRC. CONCLUSION: The multi-directional activity of coxibs, which was the reason for their effectiveness against CRC development may be the key to proposing a new target area for chemoprevention. It has been shown that celecoxib partly inhibits the activity of NF-kappaB, transcription factor involved in inflammation and carcinogenesis pathways. Modulation of its activation may be the future of effective CRC chemoprevention.
Authors:
M Spychalski; L Dziki; A Dziki
Related Documents :
3318575 - Adverse reactions to aspirin and nonsteroidal anti-inflammatory drugs.
15972345 - Long-term nsaid use in primary care: changes over a decade and nice risk factors for ga...
14585915 - Underutilization of preventive strategies in patients receiving nsaids.
8872915 - A flow-cytometric method to evaluate drug antiaggregating effect on rat neutrophils.
8845485 - Cardiotoxicity in the scid mouse following administration of doxorubicin and cyclospori...
10644815 - Immune hemolytic anemia induced by 6-mercaptopurine.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland     Volume:  9     ISSN:  1462-8910     ISO Abbreviation:  Colorectal Dis     Publication Date:  2007 Jun 
Date Detail:
Created Date:  2007-05-16     Completed Date:  2007-07-17     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  100883611     Medline TA:  Colorectal Dis     Country:  England    
Other Details:
Languages:  eng     Pagination:  397-401     Citation Subset:  IM    
Affiliation:
Department of General and Colorectal Surgery, Medical University of Lodz, Lodz, Poland. nik@toya.net.pl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenomatous Polyposis Coli / drug therapy
Colorectal Neoplasms / metabolism,  prevention & control*
Cyclooxygenase 2 Inhibitors / pharmacology,  therapeutic use*
Female
Humans
Male
NF-kappa B p50 Subunit / antagonists & inhibitors*,  drug effects
Randomized Controlled Trials as Topic
Chemical
Reg. No./Substance:
0/Cyclooxygenase 2 Inhibitors; 0/NF-kappa B p50 Subunit; 0/NFKB1 protein, human

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Should ileal pouch-anal anastomosis include mucosectomy?
Next Document:  Diagnostic precision of magnetic resonance imaging for preoperative prediction of the circumferentia...